Read the Transcript: http://to.pbs.org/hDtkA1 Are prescription-drug records confidential medical data, or can drug companies use them to market their products? The Supreme Court heard arguments on Tuesday on some states' laws aimed at curbing the marketing process known as "data mining." Ray Suarez weighs the arguments with the National Law Journal's Marcia Coyle.
Views: 1311 PBS NewsHour
Abeed Sarker, PHD, Research Associate , Informatics, Health Language Processing Lab,The University of Pennsylvania, presents at the Healthcare Informatics Presentation Series, hosted by The Department of Biomedical and Health Informatics at Children's Hospital of Philadelphia.
Views: 26 CHOP DBHi
ERIC HORVITZ Distinguished Scientist & Managing Director Microsoft Research
Views: 9 NASEM Health and Medicine Division
Russ Altman, a Stanford professor of bioengineering, genetics and medicine (and computer science, by courtesy) is using data mining methods to discover new drug interactions and side effects. Altman spoke about his research at the first EngX, a mini-conference of leading ideas from Stanford Engineering.
Views: 1013 Stanford University School of Engineering
Joint Committee on Health Care Financing held a hearing on several bills related to data mining (S. 17, S. 19, H. 109, and H. 110). These bills prevent pharmaceutical companies from buying doctors prescribing records from pharmacies and using that information to target their marketing to physicians. Jasmin Weaver spoke about the need to protect patient privacy and gave the example of CVS/Caremark marketing on behalf of Merck to their pharmacy patients. When asked by Senator Candaras, Representative Grant and Representative DAmico, why this practice was not a violation of HIPAA, Weaver and Wilkinson replied that this practice is a loophole under HIPAA and is actually allowed. This law will close that loophole for Massachusetts.
Views: 1049 HCFAMA
http://aintthatamazing.org With the help of Microsoft's data from searches on Bing, Google and Yahoo, unknown drug interactions have been found using data mining. Scientists found data showing drug interaction side effects before the FDA had been notified. This could be a remarkable tool. One hope is that search engine companies could analyze the data and ship the results to FDA, which would then screen the information and alert doctors of new potential risks. http://aintthatamazing.org
Views: 165 Bob Perry
Dr. Paea LePendu, PCCI SMU Computer Science Seminar Electronic health records contain data about patients that include laboratory test results, medication orders, vital signs, codes for various diseases and procedures, and, perhaps most importantly of all, the notes taken by doctors, nurses and other clinicians during their everyday practice of medicine. Acting quickly on this data streaming in real-time through a hospital system can very literally save lives, as we do at the Parkland Center for Clinical Informatics, for detecting and preventing sepsis. Yet, the age of data-driven medicine will truly come when computers will augment our ability to actively learn from this collective gold-mine of knowledge, which we call the patient-feature matrix.
Views: 85 Tyler Moore
Discover the reasons to study the Master in Data Mining applied to the Medicine of the hand of his academic coordinators. It is a unique formative program for professionals of the Health that they want to interpret and to extract profit of the information of his patients with the help of the technology.
Views: 208 La Salle Campus Barcelona-URL
Drug overdose and opioid-related deaths continue to increase in the United States. With access to detailed records of drug seizures, arrests, Medicaid services, pharmacy loss, ambulance and emergency room data, deaths, and more, states have the ability to combat the epidemic through insights from data analytics. Desiring to reverse this dangerous trend of drug abuse, the State of Indiana partnered with KSM Consulting, in collaboration with SAP, to develop a data analytics solution that provides meaningful information to the State. With improved insight into drug abuse trends, the State has optimized the placement of treatment centers to provide help where it’s needed most, uncovered previously unseen crime factors, such as a growing trend in pharmacy robberies, and more. In the webinar, we’ll cover: combining state and federal data sources to identify trends, defining and monitoring success through KPIs and dashboards, and funding opportunities.
Views: 123 KSM Consulting
What is PRESCRIPTION ANALYTICS? What does PRESCRIPTION ANALYTICS mean? PRESCRIPTION ANALYTICS meaning - PRESCRIPTION ANALYTICS definition - PRESCRIPTION ANALYTICS explanation. Source: Wikipedia.org article, adapted under https://creativecommons.org/licenses/by-sa/3.0/ license. SUBSCRIBE to our Google Earth flights channel - https://www.youtube.com/channel/UC6UuCPh7GrXznZi0Hz2YQnQ Prescription analytics is the practice of analyzing consumers' prescription drug histories in order to provide useful information for health insurers. In the United States, two-thirds of health insurers use prescription history reports to help identify consumers who may prove expensive to insure, and to set prices or deny coverage. The reports, created and sold by medical data brokers such as MedPoint and IntelliScript, cost about $15 each and include information going back five years covering drug names, dosage, fill dates, refills, pharmacy and physician information, and possible medical conditions. The reports also include a “risk score”, based on a health risk assessment, predicting what an individual might cost an insurer in the future, as well as listing medical conditions the person may be being treated for.
Views: 64 The Audiopedia
Opioid use disorder (OUD — the medical term for addiction to opioid substances such as prescription painkillers or heroin) is an increasingly alarming epidemic. Overdoses involving opioids killed 28,647 Americans in 2014, and the rate of opioid overdose has tripled since 2000. Recent studies estimate that 2.4 million Americans meet criteria for OUD and many more use opioids recreationally, putting themselves at significant risk for addiction, overdose, and related morbidities. In addition to its devastating consequences to individuals, OUD is estimated to have a societal cost of $55.7 billion annually. Although the root causes of America’s opioid epidemic are multifaceted, physician behavior and practice patterns play a significant role. Consider that Americans consume 80% of the global supply of all opioids despite comprising less than 5% of the global population, and the vast majority of these opioids are prescribed. Once a problem concentrated in America’s urban-poor population, OUD has spread to all corners of American society and currently exerts a significant toll on the middle class and the actively employed population. The demographic shift poses a significant threat to the productivity of the American economy: Opioid usage (by prescription or otherwise) is associated with decreased employment, increased healthcare utilization, poor workers’ compensation claim outcomes, increased rates of disability, decreased rates of return-to-work following injury, and decreased self-reported ratings of quality of life and overall health. Findings: American employers, insurers, and payers have an opportunity to address the opioid epidemic by influencing patient and physician behaviors. Specifically, by encouraging and rewarding patient visits to high quality physicians who demonstrate responsible opioid prescription patterns. By identifying, rewarding, and spreading the best-practices of high-quality physicians, Grand Rounds promotes primary prevention of the OUD epidemic within the covered populations of our customers and partners. We agree with experts in the field that prioritizing a primary prevention strategy is key to combating the opioid epidemic, especially given the unique features of OUD that make secondary prevention strategies particularly difficult and resource intensive. Through our unique approach to data analytics and physician quality, Grand Rounds has identified significant regional variation in opioid prescription patterns within specialties. Furthermore, this variation can be predicted by our assessments of physician quality. Focusing specifically on the specialties of pain management, orthopedics, and primary care (the three highest opioid prescribing specialties) we find significant variation in the use of evidence-based, multidisciplinary treatments for chronic pain, which can be predicted by our assessments of physician quality.
Views: 191 Stanford Medicine X
Group Of Medicine Or Drugs In Hindi ◆Thanks For Watching◆ Subscribe For More Updates.. Mail Id - [email protected] Instgram : https://www.instagram.com/gyanear Disclaimer:All information is based on the data collected,consult a doctor before using any medication. Some Contents Are Used For Educational Purpose Under Fair Use.
Views: 188202 Gyanear
Intel's AI platform for pharmacological clinical trials. For more information please contact [email protected] Subscribe now to Intel Business on YouTube: http://intel.ly/intelitcenteryt About Intel Business: Get all the IT info you need, right here. From data center to devices, the Intel® Business Center has the resources, guidance, and expert insights you need to get your IT projects done right. Connect with Intel Business: Visit Intel Business's WEBSITE: http://intel.ly/itcenter Follow Intel Business on TWITTER: https://twitter.com/IntelBusiness Follow Intel Business on LINKEDIN: https://www.linkedin.com/showcase/intel-business/ Follow Intel Business on FACEBOOK: https://www.facebook.com/IntelBusiness Intel ®Pharma Analytics Platform | Intel Business https://www.youtube.com/intelitcenter
Views: 2071 Intel Business
The lecture will combine studies in the fields of medicine and digital health. The lecture will introduce the latest advancements in personalized drug selection using a computer and data analysis. Will a computer assign personalized drug treatments for each patient in the future? How can big data be used for drug treatment? About the lecturer: Marina Tsadkin-Tamir, clinical pharmacologist, PhD from Ben Gurion University. Has 20 years of experience in the fields of biotechnology and pharmacology. Postdoc in Tel Aviv University in the field of nano-particles and data mining. Consultant for the News Company and Mako in the field of toxicology. Lecturer in the Ramat Gan College in the fields of pharmacology and microbiology. ההרצאה תשלב מחקרים בתחומי התרופות והדיגיטל. בהרצאה יוצגו פיתוחים אחרונים במתן תרופות אישיות בעזרת מחשב וניתוח נתונים. האם בעתיד מחשב ירשום תרופות מותאמות אישית לכל חולה? כיצד ניתן לרתום טכנולוגיות ביג דאטה לצורכי טיפול תרופתי? על המרצה: מרינה צדקין-תמיר, פרמקולוגית קלינית, PhD מאוניברסיטת בן גוריון בנגב. בעלת ניסיון של 20 שנה בתחומי הביוטכנולוגיה והפרמקולוגיה. פוסטדוק מאוניברסיטת תל אביב בתחום ננו-חלקיקים ודאטה מיינינג. יועצת לחברת החדשות ומקו בתחום טוקסיקולוגיה. מרצה במכללה אקדמית רמת גן בתחומים של פרמקולוגיה ומיקרוביולוגיה.
Views: 37 Ilya Vainberg Slutzkin
Medication non-adherence is a major concern in the healthcare industry and has led to increases in health risks and medical costs. For many neurological diseases, adherence to medication regimens can be assessed by observing movement patterns. However, physician observations are typically assessed based on visual inspection of movement and are limited to clinical testing procedures. Consequently, medication adherence is difficult to measure when patients are away from the clinical setting. The authors propose a data mining driven methodology that uses low cost, non-wearable multimodal sensors to model and predict patients' adherence to medication protocols, based on variations in their gait. The authors conduct a study involving Parkinson's disease patients that are “on” and “off” their medication in order to determine the statistical validity of the methodology. The data acquired can then be used to quantify patients' adherence while away from the clinic. Accordingly, this data-driven system may allow for early warnings regarding patient safety. Using whole-body movement data readings from the patients, the authors were able to discriminate between PD patients on and off medication, with accuracies greater than 97% for some patients using an individually customized model and accuracies of 78% for a generalized model containing multiple patient gait data. The proposed methodology and study demonstrate the potential and effectiveness of using low cost, non-wearable hardware and data mining models to monitor medication adherence outside of the traditional healthcare facility. These innovations may allow for cost effective, remote monitoring of treatment of neurological diseases. Source: http://www.sciencedirect.com/science/article/pii/S0010482515002930
A recent study found that by tracking search terms online, it is possible to predict side effects of drug interactions faster than the FDA. Annie takes a look at the study, and the similarities to Google Flu Trends, which also mines online data to establish health trends. Unreported Side Effects of Drugs Found Using Internet, New York Times: http://www.nytimes.com/2013/03/07/science/unreported-side-effects-of-drugs-found-using-internet-data-study-finds.html?_r=0 ***Join Scott & Annie for a LIVE Q&A Google+ Hangout Event! Monday, March 11th at 5pm EST/2pm PST: http://goo.gl/UWUEn *** ***Don't Forget: Send us a Video Response with a question for Scott or Annie and win a FREE Tech Feed T-Shirt!*** Please Subscribe: http://www.youtube.com/subscription_center?add_user=thetechfeed Google+: http://gplus.to/techfeed Facebook: http://www.facebook.com/techfeedtv?ref=ts&fref=ts Twitter: http://www.twitter.com/TECHFEED_News Follow Annie on Twitter: http://www.twitter.com/anniegaus And on Facebook: http://www.facebook.com/anniegaus Host: Annie Gaus Producer: Lauren Rudser Associate Producers: Todd Boudreaux, Chastity Vicencio Editor: Frank Knight
Views: 5149 What's the Big Deal?
If you're not paying, you're not the customer--you're the product. #AdamRuinsEverything Watch an all-new Adam Ruins Everything on truTV every Tuesday 10/9C Catch up with clips & full episodes of Adam Ruins Everything at truTV.com/adamruinseverything Like Adam Ruins Everything on Facebook at: facebook.com/truTVAdamRuinsEverything/ Follow Adam Ruins Everything on Twitter at: twitter.com/adamruins See more http://www.collegehumor.com LIKE us on: http://www.facebook.com/collegehumor FOLLOW us on: http://www.twitter.com/collegehumor FOLLOW us on: http://www.collegehumor.tumblr.com
Views: 6035708 CollegeHumor
PyData Amsterdam 2018 Machine learning plays an important role in cancer research. In this talk, we’ll tackle the challenge of predicting which patients are likely to respond to given anti-cancer treatments. In doing so, we’ll show how tools such as Snakemake/Bioconda can be used to create reproducible workflows and illustrate the challenges of interpreting predictive models in large, highly-correlated feature spaces. Slides: https://www.slideshare.net/PyData/from-cells-to-drug-responses-machine-learning-in-cancer-research-julian-de-ruiter-nanne-aben -- www.pydata.org PyData is an educational program of NumFOCUS, a 501(c)3 non-profit organization in the United States. PyData provides a forum for the international community of users and developers of data analysis tools to share ideas and learn from each other. The global PyData network promotes discussion of best practices, new approaches, and emerging technologies for data management, processing, analytics, and visualization. PyData communities approach data science using many languages, including (but not limited to) Python, Julia, and R. PyData conferences aim to be accessible and community-driven, with novice to advanced level presentations. PyData tutorials and talks bring attendees the latest project features along with cutting-edge use cases.
Views: 318 PyData
The recent Data Analytics in Pharma Development conference inspired many with the truth of how data can power the future of medicine. In this short video, Nigel Hughes, Scientific Director, RMEDS Quantitative Sciences at Janssen R&D provides a few key lessons on the matter.
Views: 264 Pharma IQ
As healthcare organizations gain access to more information, data volume and poor integration have stymied actionable insights. As a result, these organizations rely increasingly on complex systems and predictive tools, which has led to a divide between technical analysts and decision-makers. Palantir bridges this gap using an integrated set of big-data technologies coupled with an interactive UI that empower analysts at all levels of the healthcare continuum to derive insights. We will demonstrate how a health insurance provider discovers new patterns of fraud beginning at the macro level and narrowing down to specific facilities. At the other end of the spectrum, we will show how a physician informs his treatment for a patient with diabetes through hospital comparisons. This demo uses ten years of Medicare claims consisting of 1.2 billion records integrated with public data sources.
Views: 9262 Palantir
Adherence Health is a digital health company focused on medication adherence, patient engagement, and data aggregation. The company’s eMedonline® platform for managing adherence and outcomes has improved adherence from 50% to 95+% in multiple randomized-control clinical studies. eMedonline combines communication and information technologies to create a “conversation” between patients and providers around medication adherence and related outcomes. Its web-based server application collects and codifies data sent to it about patient-specific dosing events and outcomes for disease management and data mining. eMedonline offers a universal platform that can manage all forms of medications—oral, injectable, transdermal. It provides dose-by-dose monitoring for the most complex regimens as acts as a Mini-Patient Record by providing a personalized Body Map and therapy plan to the patient, while enabling connectivity to electronic health record systems and pharmacy information systems.
Views: 86 Adherence Health - eMedonline
On January 13, 2014 the Southwestern Law School Federalist Society student chapter hosted a debate about the FDA's role in regulating off-label drug use featuring Professor Richard Epstein, the Laurence A. Tisch Professor of Law at NYU and the Kirsten Bedford Senior Fellow at the Hoover Institution, and Ryan Abbott, Associate Professor of Law at Southwestern Law School and Visiting Assistant Professor of Medicine at the David Geffen School of Medicine at UCLA. Before a drug can be sold legally in the United States, the Food and Drug Administration (FDA) must approve it as safe and effective for a particular indication or use — the use then appears on the drug's label. Federal law, however, allows doctors to prescribe drugs that the FDA has approved for one indication for any other indication, even though the FDA never evaluated the safety or efficacy of the drug for that use. Off-label prescribing is an integral part of modern-day medicine. Patients may benefit when they receive drugs or devices in contexts not approved by the FDA. In fact, in some instances an off-label use may be the standard of care for a particular health problem. However, off-label prescribing can also harm patients, especially when an off-label use lacks a solid evidentiary basis. For this reason, the FDA forbids drug companies from promoting their own products for off-label use, except for certain activities such as disseminating research literature and sponsoring educational programs. In recent years, civil and criminal actions against drug companies for illegal promotion for off-label use have proliferated, leading to many large settlements. For example, in July 2012, GlaxoSmithKline pled guilty and paid $3 billion to resolve criminal and civil liability arising from the company's unlawful prescription drug promotion, failure to report safety data, and false price reporting practices. As a result of this recent litigation, many have questioned the FDA's current role in regulation of off-label use and whether more or less intervention is needed. This debate sought to address these very issues. Both Professors have written about FDA regulations. For example, Professor Epstein in his book, Overdose: How Excessive Government Regulation Stifles Pharmaceutical Innovation, and in an article in the Minnesota Law Review, "Against Permititis: Why Voluntary Organizations Should Regulate the Use of Cancer Drugs." Professor Abbott has written about FDA regulations in the Iowa Law Review, Big Data and Pharmacovigilance: Using Health Information Exchanges to Revolutionize Drug Safety, and he has an article forthcoming in the Duke Law Journal with Ian Ayres at Yale Law School on Mechanisms for Regulating Off-Label Drug Use.
Views: 2773 Ryan Abbott
Overview of important precautions with prednisone use. Learn more at: http://www.drugs.com/prednisone.html Drugs.com is the most popular, comprehensive and up-to-date source of drug information online. Providing free, peer-reviewed, accurate and independent data on more than 24,000 prescription drugs, over-the-counter medicines & natural products. Find helpful tools, wallet size personal medication records, mobile applications and more.
Views: 5929 Drugs.com
This talk was given at a local TEDx event, produced independently of the TED Conferences. Why are there two rock songs about lithium but none about, say, beryllium? In a talk at once funny, profound, and educational, Ben Lillie weaves a tale about the origin of the mysterious element we know as lithium. Ben Lillie is a former particle physicist and the director of The Story Collider, a live series that features true stories about science.
Views: 214906 TEDx Talks
Data mining (the analysis step of the "Knowledge Discovery in Databases" process, or KDD), an interdisciplinary subfield of computer science, is the computational process of discovering patterns in large data sets involving methods at the intersection of artificial intelligence, machine learning, statistics, and database systems. The overall goal of the data mining process is to extract information from a data set and transform it into an understandable structure for further use. Aside from the raw analysis step, it involves database and data management aspects, data pre-processing, model and inference considerations, interestingness metrics, complexity considerations, post-processing of discovered structures, visualization, and online updating. The term is a misnomer, because the goal is the extraction of patterns and knowledge from large amount of data, not the extraction of data itself. It also is a buzzword, and is frequently also applied to any form of large-scale data or information processing (collection, extraction, warehousing, analysis, and statistics) as well as any application of computer decision support system, including artificial intelligence, machine learning, and business intelligence. The popular book "Data mining: Practical machine learning tools and techniques with Java" (which covers mostly machine learning material) was originally to be named just "Practical machine learning", and the term "data mining" was only added for marketing reasons. Often the more general terms "(large scale) data analysis", or "analytics" -- or when referring to actual methods, artificial intelligence and machine learning -- are more appropriate. This video is targeted to blind users. Attribution: Article text available under CC-BY-SA Creative Commons image source in video
Views: 1712 Audiopedia
This FDA Consumer Update video provides helpful tips to avoid the three main types of interactions: drugs with food and beverages, drugs with dietary supplements, and drugs with other drugs. Learn more at http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm096386.htm [vpdrugs]
Views: 24464 U.S. Food and Drug Administration
When it comes to drug pricing, there is no incentive for any one part of the U.S. health care system to change. So it will take a dramatic shift for patients to see lower drug prices any time soon. http://signup.axios.com/
Views: 2102 Axios
In our ASA's Patient-Focused Update, Chief Science Officer Dr. Jahan Marcu Ph.D. and Policy Analyst David Mangone join me to discuss the need for cannabis lab certification and the recent movement in Congress on bills benefiting medical marijuana patients. In Drug War Data Mining, Drug Policy Alliance has a new guide for lawmakers explaining how to better frame and talk about issues surrounding drug policy reform. Our Northeast Cannabis Chronicle features Jared Moffat from Regulate Rhode Island, discussing why his group and others are boycotting the creation of a state marijuana legalization study commission. And in the Radical Rant, I expose yet another way Jeff Sessions wants to turn back the clock on drug policy reform by reinvigorating "equitable sharing" and "adoptive forfeitures" that expand civil asset forfeiture. Live stream of the recording of The Marijuana Agenda podcast every weekday at 3pm Pacific. Daily news/talk radio by, for, and about the cannabis community, marijuana law reform, law enforcement, civil rights, justice, and politics. Podcast available at http://MJAgenda.com. FEATURING PODCAST SEGMENTS FROM THE TOP ORGANIZATIONS IN MARIJUANA WEEK OF JULY 10, 2017 (CENTRAL ROTATION) MON: Cannabis Q&A with Dr. Mitch Earleywine; Midwest Cannabis Chronicle (ND, SD, NE, KS, MN, IA, MO, WI, IL, MI, IN, OH) TUE: A Sensible Future (SSDP); Freedom Leaf Preview WED: Cannabis Minority Report (BLACK Marijuana Magazine); Southwest Cannabis Chronicle (TX, OK, NM, AZ, NV, HI) THU: Police for Reform (LEAP); What About the Children (Moms for Marijuana) FRI: Marijuana Policy Insider (MPP); Pot & Public Policy (Brookings Institute) WEEK OF JULY 17, 2017 (EASTERN ROTATION) MON: ASA's Patient-Focused Update (Americans for Safe Access); Northeast Cannabis Chronicle (NY, PA, MD, DE, DC, NJ, MA, CT, RI, VT, NH, ME) TUE: Expanded Mind (MAPS); Shark Sessions (The Marijuana Show) WED: Hempday Humpday Update (HempAce Int'l); Southeast Cannabis Chronicle (AR, LA, MS, AL, GA, FL, SC, NC, VA, WV, KY, TN) THU: Voice of the Industry (NCIA); Cannabis Sports Medicine (Gridiron Cannabis) FRI: Drug Policy Reform Update (DPA); Government at Work WEEK OF JULY 24, 2017 (WESTERN ROTATION) MON: Cannabis Q&A with Dr. Mitch Earleywine; California Cannabis Chonicle TUE: A Sensible Future (SSDP); Activist's Agenda WED: Cannabis Minority Report (BLACK Marijuana Magazine); Northwest Cannabis Chronicle (OR, WA, AK) THU: Police for Reform (LEAP); Cultivator's Corner with Jorge Cervantes (MarijuanaGrowing.com) FRI: Marijuana Policy Insider (MPP); Rocky Mountain Cannabis Chronicle (CO, UT, WY, ID, MT) WEEK OF JULY 31, 2017 (INTERNATIONAL ROTATION) MON: ASA's Patient-Focused Update (Americans for Safe Access); Canadian Cannabis Chronicle TUE: Expanded Mind (MAPS); Freedom is NORML WED: Hempday Humpday Update (HempAce Int'l); Veterans of Compassion (Veterans Cannabis Group) THU: Voice of the Industry (NCIA); Reformer's Reader FRI: Drug Policy Reform Update (DPA); United Kingdom Cannabis Chronicle
Views: 360 Russ Belville
ESR Blood Test In Hindi | Gyanear Hi Friends !! I'm Dr.Shivam Vishwakarma welcome to Gyanear ◆Thanks For Watching◆ Subscribe For More Updates.. Mail Id - [email protected] Instgram : https://www.instagram.com/gyanear Disclaimer:All information is based on the data collected,consult a doctor before using any medication. Some Contents Are Used For Educational Purpose Under Fair Use.
Views: 158047 Gyanear
Speaker: Ola Caster (2017) This two part talk covers the concepts, principles and methods in benefit-risk assessment and why it is an important area. Dr. Ola Caster has worked at UMC since 2007. His primary focus is research on quantitative methods for benefit-risk assessment. Another area of interest is exploratory analysis of VigiBase and other post-marketing data sources, for example to support the early detection of potential drug-drug interactions and drug dependence issues. Ola is also involved in some signal detection and analysis work. Handouts available here: https://bit.ly/2CJ3Byd Follow UMC: Twitter: http://www.twitter.com/UMCGlobalSafety Facebook: http://www.facebook.com/UppsalaMonitoringCentre
Views: 3725 Uppsala Monitoring Centre
DUI Defense Attorney Kevin Hayslett gives counsel. http://www.carlsonmeissner.com/practice-areas/dwi-dui-defense-attorneys.aspx 1-800-LAW-5655
Views: 207 CMHartHayslett
This application compiles data reported through the FDA's FDA Adverse Event Reporting System (FAERS). QlikView allows the users to see by manufacturer and/or drug name the adverse events reported. Users can also see the frequency of adverse events per 100 days. Using comparative analysis, users can also see a side by side comparison of the total number of adverse events reported when a patient was prescribed a certain combination of reported drugs .
Views: 1870 QlikView Demos
Many people have to take a bunch of prescription drugs, but how do doctors test drugs interactions to keep them from killing you? Is It Unsafe To Take Expired Medicine? ►►►► http://dne.ws/1HHP4Qz Sign Up For The TestTube Newsletter Here ►►►► http://dne.ws/1McUJdm Read More: Drug Drug Interactions http://www.drugs.com/drug-interactions/adalimumab.html Discovering New Drug-Drug Interactions by Text-Mining the Biomedical Literature http://nlp.stanford.edu/courses/cs224n/2011/reports/blpercha.pdf “Americans are living longer than ever before, and with that increased age comes a greater reliance on pharmaceuticals. For example, recent estimates by Kaiser Permanente indicate that the average 70-year-old Americans over 30 prescriptions per year.” ____________________ DNews is dedicated to satisfying your curiosity and to bringing you mind-bending stories & perspectives you won't find anywhere else! New videos twice daily. Watch More DNews on TestTube http://testtube.com/dnews Subscribe now! http://www.youtube.com/subscription_center?add_user=dnewschannel DNews on Twitter http://twitter.com/dnews Trace Dominguez on Twitter https://twitter.com/tracedominguez Julia Wilde on Twitter https://twitter.com/julia_sci DNews on Facebook https://facebook.com/DiscoveryNews DNews on Google+ http://gplus.to/dnews Discovery News http://discoverynews.com Download the TestTube App: http://testu.be/1ndmmMq Sign Up For The TestTube Mailing List: http://dne.ws/1McUJdm
Views: 64500 Seeker
To get this project in ONLINE or through TRAINING Sessions, Contact: JP INFOTECH, 45, KAMARAJ SALAI, THATTANCHAVADY, PUDUCHERRY-9 Landmark: Opposite to Thattanchavady Industrial Estate, Next to VVP Nagar Arch. Mobile: (0) 9952649690 , Email: [email protected], web: www.jpinfotech.org Blog: www.jpinfotech.blogspot.com A Method for Mining Infrequent Causal Associations and Its Application in Finding Adverse Drug Reaction Signal Pairs 2013 IEEE In many real-world applications, it is important to mine causal relationships where an event or event pattern causes certain outcomes with low probability. Discovering this kind of causal relationships can help us prevent or correct negative outcomes caused by their antecedents. In this paper, we propose an innovative data mining framework and apply it to mine potential causal associations in electronic patient data sets where the drug-related events of interest occur infrequently. Specifically, we created a novel interestingness measure, exclusive causal-leverage, based on a computational, fuzzy recognition-primed decision (RPD) model that we previously developed. On the basis of this new measure, a data mining algorithm was developed to mine the causal relationship between drugs and their associated adverse drug reactions (ADRs). The algorithm was tested on real patient data retrieved from the Veterans Affairs Medical Center in Detroit, Michigan. The retrieved data included 16,206 patients (15,605 male, 601 female). The exclusive causal-leverage was employed to rank the potential causal associations between each of the three selected drugs (i.e., enalapril, pravastatin, and rosuvastatin) and 3,954 recorded symptoms, each of which corresponded to a potential ADR. The top10 drug-symptom pairs for each drug were evaluated by the physicians on our project team. The numbers of symptoms considered as likely real ADRs for enalapril, pravastatin, and rosuvastatin were 8, 7, and 6, respectively. These preliminary results indicate the usefulness of our method in finding potential ADR signal pairs for further analysis (e.g., epidemiology study) and investigation (e.g., case review) by drug safety professionals.
Views: 416 jpinfotechprojects
Self Employed Tax Software : https://quickbooks.grsm.io/JackPitman eBay DropShipping Course - https://goo.gl/bW6u7c Monetizing YouTube as a Lifestyle - https://goo.gl/ic8UvU Schedule a Free Recorded Video with me Here : https://goo.gl/FxEsem Interested in Drop Shipping Software? There is loads available. Check them out below ___ All-In-One-Drop-Shipping-Suites These tools all allow you to List items, Reprice items, and do some form of product research or sniping for one monthly price. DSM Tool: https://www.dsmtool.com/?t=88c174cd14d23dc4cc4e9b5df9401938 AutoDSTool https://autodstools.com/register/?name=Jack_p Pricematik https://www.pricematik.com/?ref=5fdc013a-848e-45a6-b480-ba575af3d63a SKUgrid http://skugrid.com/web/?ref=lymeliterate This tool pairs with most Listers and keeps track of price changes. Product Research and Sniping Tools These tools allow you to identify source URLS of items that other people have already sold before. ZikAnalytics https://zikanalytics.com/Registration?ReferrerId=54749 JitBit Macro Recorder: Learning to automate tasks using Macros can save you exponential a mounts of time. I use JitBit Macro Recorder for my macros. MR Basic: https://jitbit.fastspring.com/jitbit/instant/macro-recorder-basic?source=gullygames MR Pro: https://jitbit.fastspring.com/jitbit/instant/macro-recorder-pro?source=gullygames MR Premium: https://jitbit.fastspring.com/jitbit/instant/macro-recorder-premium?source=gullygames Kabbage Business Loans: You can sync your paypal account up with kabbage and get a business loan. Kabbage can be very useful for cashflow. https://www.kabbage.com/?refid=krpdebcce87&corrdata=Invite Hydra Lister http://start.hydra-lister.com/JackPitman Hydra is my favorite tool for bulk posting because the price of Hydra stays the same no matter how many items you post with it. It allows me to quickly and easily post 100,000 + items a month SKUgrid http://skugrid.com/web/?ref=lymeliterate This tool pairs with most Listers and keeps track of price changes. Infinii https://infinii.com/members/signup-prime/gullygames Infinii is a "Suite" that allows you to post items and track items as well. It has an extensive database of training videos and an MLM format affiliate program however and is not competitive software. Address Copier https://dropship4arbitrage.com/aff/999 This tool allows you to copy the buyer's whole address at once for walmart items instead of copying each field one at a time. Fees Delister https://feesdelister.top/aff/1499 This tool allows you to delete items that have not produced a sale incredibly quickly. You can delete items that have not sold in 30 days, 60 days, 90 days, and more! Tracking Automation (Update Duck) https://www.updateduck.com/?r=JackPitman This tool automatically loads your tracking numbers to eBay from your email account. I personally know the developer. Tracking Automation (Pigeon Tracker) This tool automatically loads your tracking numbers to eBay from your email account. https://dropship4arbitrage.com/aff/999 __ __ Other Drop Shipping YouTube Channels - Dropship Tyler https://www.youtube.com/channel/UCRHlp5XPTX1q4cANdrHEYKA Tyler runs a dropshipping channel and shares information about his ecommerce business. Tyler has helped me (Jack) with a few things over the years. He is a good guy. Thai Nguyen https://www.youtube.com/channel/UC3yhcf_gCSZZUtk3gLma_6g Thai does regular videos about dropshipping on eBay Austin Reed https://www.youtube.com/channel/UCDBTWPyzprM5ZfM_69O1F5Q Austin is doing a $10K Profit in a Month challenge Paul Lipsky https://www.youtube.com/channel/UCmeU2DYiVy80wMBGZzEWnbw Paul runs a YouTube channel about Drop Shipping sourcing from Home Depot using Title Optimiation and scaling through Virtual Assistance. Broke To Boss Girl https://www.youtube.com/channel/UCi7u9MaAAS_ArjRcULAYTQA Becky runs a YouTube channel about drop shipping from the UK. Dropshipping Amateur Guru https://www.youtube.com/user/Charsdx Carlos runs a YouTube channel about drop shipping in Spanish.
Views: 567 Jack Pitman
Sign up for Top Class Actions' FREE weekly newsletter: https://topclassactions.com/ The Weather Channel app improperly advertises itself as a weather service when its primary objective is to collect and sell user data, according to a recent lawsuit. On Thursday, Los Angeles residents filed a lawsuit against TWC Product and Technology LLC, the company that runs The Weather Channel, claiming it violates California law by engaging in unfair competition. Ring of Fire’s Farron Cousins discusses this with Scott Hardy from Top Class Actions. Link – https://topclassactions.com/lawsuit-settlements/consumer-products/mobile-apps/875361-the-weather-channel-didnt-disclose-data-mining-la-lawsuit-says/ Become a member today!: https://www.youtube.com/channel/UCYWIEbibRcZav6xMLo9qWWw/join Support us by becoming a monthly patron on Patreon, and help keep progressive media alive!: https://www.patreon.com/TheRingofFire Spread the word! LIKE and SHARE this video or leave a comment to help direct attention to the stories that matter. And SUBSCRIBE to stay connected with Ring of Fire's video content! Support Ring of Fire by subscribing to our YouTube channel: https://www.youtube.com/theringoffire Be sociable! Follow us on: Facebook: http://www.facebook.com/RingofFireRadio Twitter: http://www.twitter.com/RingofFireRadio Google+: http://plus.google.com/118415831573195648557 Instagram: https://www.instagram.com/ringoffirenetwork/ Follow more of our stories at http://www.TROFIRE.com Subscribe to our podcast: http://www.ROFPodcast.com #rof #trofire #theringoffire #progressivenews
Views: 3293 The Ring of Fire
Final Year IEEE Projects for BE, B.Tech, ME, M.Tech,M.Sc, MCA & Diploma Students latest Java, .Net, Matlab, NS2, Android, Embedded,Mechanical, Robtics, VLSI, Power Electronics, IEEE projects are given absolutely complete working product and document providing with real time Software & Embedded training...... ---------------------------------------------------------------- JAVA & .NET PROJECTS: Networking, Network Security, Data Mining, Cloud Computing, Grid Computing, Web Services, Mobile Computing, Software Engineering, Image Processing, E-Commerce, Games App, Multimedia, etc., EMBEDDED SYSTEMS: Embedded Systems,Micro Controllers, DSC & DSP, VLSI Design, Biometrics, RFID, Finger Print, Smart Cards, IRIS, Bar Code, Bluetooth, Zigbee, GPS, Voice Control, Remote System, Power Electronics, etc., ROBOTICS PROJECTS: Mobile Robots, Service Robots, Industrial Robots, Defence Robots, Spy Robot, Artificial Robots, Automated Machine Control, Stair Climbing, Cleaning, Painting, Industry Security Robots, etc., MOBILE APPLICATION (ANDROID & J2ME): Android Application, Web Services, Wireless Application, Bluetooth Application, WiFi Application, Mobile Security, Multimedia Projects, Multi Media, E-Commerce, Games Application, etc., MECHANICAL PROJECTS: Auto Mobiles, Hydraulics, Robotics, Air Assisted Exhaust Breaking System, Automatic Trolley for Material Handling System in Industry, Hydraulics And Pneumatics, CAD/CAM/CAE Projects, Special Purpose Hydraulics And Pneumatics, CATIA, ANSYS, 3D Model Animations, etc., CONTACT US: ECWAY TECHNOLOGIES 15/1 Sathiyamoorthi Nagar, 2nd Cross, Thanthonimalai(Opp To Govt. Arts College) Karur-639 005. TamilNadu , India. Cell: +91 9894917187. Website: www.ecwayprojects.com | www.ecwaytechnologies.com Mail to: [email protected]
Views: 17 Ecway Karur
Associate Professor Thomas Ostenfeld Larsen, who heads the research group Natural Product Discovery at DTU Systems Biology talks about the group’s discovery and engineering of novel natural products from an array of organisms. Products that may be used to solve some of the challenges society face today. One example is a very large project where they sequence all known species in genus aspergillus. This will give them first hand access to genomics driven discovery of silent gene clusters and engineering of these to produce the potentially new drug lead candidate of the future.
Views: 698 Mette Haagen
How does law enforcement use data to prevent fraud? Kelly Tshibaka, Chief Data Officer of the U.S. Postal Service Office of Inspector General, and Caryl Brzymialkiewicz, Assistant Inspector General & Chief Data Officer at U.S. Department of Health and Human Services Office of Inspector General, speak with CXOTalk about how different agencies at the Office of Inspector General use data analytics. For more information, see https://www.cxotalk.com/episode/fraud-prevention-data-analytics-law-enforcement Since 2015, Tshibaka has served as Chief Data Officer in the U.S. Postal Service Office of Inspector General (OIG), where data analytics has resulted in more than $920 million in financial impact or audit findings in FY16. She previously served as the Acting Inspector General of the Federal Trade Commission, worked in the Office of the Director for National Intelligence (ODNI), and served as the Special Assistant to the Department of Justice Inspector General. As the first Chief Data Officer for the OIG within the Department of Health and Human Services (HHS), Brzymialkiewicz is focused on providing more and better access to data and analytics; accelerate analytics for use in audits, investigations, evaluations, and compliance oversight; and enhance OIG’s use of data to make more informed decisions. She previously served as the Deputy Assistant Secretary for Risk and Decision Analysis at the Department of Homeland Security (DHS). She also previously served as the Operations Research Division Chief at the Joint Improvised Explosive Device Defeat Organization, and led a team of analysts at the Center for Naval Analyses. From the transcript: Michael Krigsman: (05:01) And, Caryl, can you maybe elaborate on this, because I think it’s a very interesting point. So, you report to two separate people in order to ensure that as an inspector general, or working in the office of the inspector general, that you maintain independence. That’s very important. Could you elaborate on that point, please? Caryl Brzymialkiewicz: (05:23) Yes. Absolutely. So, for our organization, for example, health and human services is a trillion-dollar portfolio. So, our responsibility is to provide oversight for the agency. Think about centers for Medicaid, Medicare, think about the Center for Disease Control, the Food and Drug Administration, the National Institutes of Health, and many, many other agencies. But, that duel-reporting structure really allows for, as Kelly mentioned, that the independence… We want to give the information, first and foremost, to the agency to help make the agency better but we also know that there’s a lot of things that Congress is expecting us to make sure we’re using the dollars as most effectively as we can. (05:59) One thing I will say, too, that’s interesting about the law enforcement angle that you mentioned, we’re not just trying to knock on doors within the agency and figure out where people may or may not be filing the right paperwork, if you will. Really, what we’re trying to do is protect the integrity of the programs to make sure that the beneficiaries of those programs are getting what they need, and to make sure that outside entities aren’t… You know, when we think about fraud, the outside entities aren’t taking advantage of the programs as well. So, it’s not just an internal focus, it’s not supposed to be a “Gotcha!” moment. Kelly Tshibaka: (15:40) We start with the business question. What am I trying to answer? So, like, to give you an example, we wanted to find out, in the data that we have and the information we have, can we put together any trends or any ideas about how to solve this question? And interestingly, just another shout-out, like Caryl was saying for agents, we can't do our data analytics job without a business understanding of what's going on. So, we have to partner closely with the agents and want the auditors to understand how data are collected, what it's used for, how they understand it. Because, once we understand a little bit more than their business and what they're trying to do, then we can work with the data. Our teams can work with the data in order to figure out how to best use the data and look through it in order to answer those business questions so we get business understanding from our auditors and our agents and oftentimes, even from the people in the agencies that we oversee. (17:08) So, to answer your question specifically, Michael, we pull it from the agency, but we also pull it from other agencies if we need it. We’ll pull it from private companies if we need it, and if we can get it. You’ll be surprised what’s even just publicly available on the internet that we can pull and if we can get it into a usable format, then it makes it a lot easier for us to work with it and come up with insights that people can take action on.
Views: 5361 CXOTALK
Major pharmaceutical companies are reportedly recruiting thousands of recreational drug users to test a new generation of medicines that deter addiction, which could have a significant impact in the fight against prescription drug addiction. Financial Times reporter David Crow joins Hari Sreenivasan to explain the drug tests.
Views: 1379 PBS NewsHour
Key players in drug abuse industry include Biomedical Diagnostics, BioMerieux, Abbott Laboratories, Bio-Rad, Dako, DiaSorin, Eiken and Fujirebio, Beckman Coulter. KEY BENEFITS • The report provide strategic intelligence about key developmental plans adopted by top companies so that future market trends in drug abuse market is justified • Market estimations derived in this report are based on primary and secondary data analysis that provides micro level intelligence of drug abuse market • Key regulatory issues and reimbursement scenario is analyzed in this market to get intelligence about future market growth in drug abuse market • Top investment pockets that generate more growth in terms of revenues are mentioned with info-graphic analysis • Market analysis and intelligence of drug abuse market is performed according to end-users, equipments and geographic segments http://www.bigmarketresearch.com/drug-abuse-testing-market
Views: 10 Christopher Copeley
Facts: In 2007, the Vermont legislature passed a law that banned the sale, transmission or use of prescriber-identifiable data (''PI data'') for marketing or promoting a prescription drug without the consent of the prescriber. The law also prohibited the sale, license or exchange for value of PI data for marketing or promoting a prescription drug. Three companies -- IMS Health, Verispan and Source Healthcare Analytics, a unit of Dutch publisher Wolters Kluwer -- that collect and sell such data and by a trade group for pharmaceutical manufacturers challenged the law. The U.S. Court of Appeals for the 2nd Circuit struck down the measure, holding that it violated the First Amendment because it restricts the speech rights of data miners without directly advancing legitimate state interests. Question: Does a Vermont state statute banning the sale, transmission or use of prescriber-identifiable data, absent prescriber consent, unconstitutionally restrict the free speech rights of pharmaceutical research companies, manufacturers and others to use that data? Conclusion: Yes. The Supreme Court affirmed the lower court order in an opinion by Justice Anthony Kennedy. "Vermont's statute, which imposes content-and speaker-based burdens on protected expression, is subject to heightened judicial scrutiny," Kennedy wrote. Meanwhile, Justice Stephen Breyer dissented, joined by Justices Ruth Bader Ginsburg and Elena Kagan. "The First Amendment does not require courts to apply a special 'heightened' standard of review when reviewing such an effort," Breyer wrote. "And, in any event, the statute meets the First Amendment standard this Court has previously applied when the government seeks to regulate commercial speech." For more information about this case see: https://www.oyez.org/cases/2010/10-779 Section 1: 00:00:05 Section 2: 00:20:36 Section 3: 00:31:30 Section 4: 01:03:23 PuppyJusticeAutomated videos are created by a program written by Adam Schwalm. This program is available on github here: https://github.com/ALSchwalm/PuppyJusticeAutomated The audio and transcript used in this video is provided by the Chicago-Kent College of Law under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License. See this link for details: https://creativecommons.org/licenses/by-nc/4.0/
Views: 274 PuppyJusticeAutomated
Session 3: Analysis of medication errors resulting in harm Speaker: Phil Tregunno, Medicines and Healthcare products Regulatory Agency, United Kingdom Medication errors workshop 28 February - 1 March 2013
Views: 339 emainfo
SPIRO SOLUTIONS PRIVATE LIMITED For ECE,EEE,E&I, E&C & Mechanical,Civil, Bio-Medical #1, C.V.R Complex, Singaravelu St, T.Nagar, Chennai - 17, (Behind BIG BAZAAR)Tamilnadu,India Mobile : +91-9962 067 067, +91-9176 499 499 Landline : 044-4264 1213 Email: [email protected] For IT, CSE, MSC, MCA, BSC(CS)B.COM(cs) #78, 3rd Floor, Usman Road, T.Nagar, Chennai-17. (Upstair Hotel Saravana Bhavan) Tamilnadu,India Mobile: +91-9791 044 044, +91-9176 644 044 E-Mail: [email protected]
Views: 44 spiroprojects